NASDAQ : CNXU
Conexeu Sciences Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 87.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 12.70M | 3.66M | 405.31K | 35.96K |
| Research & Development | 471.48K | 272.70K | 237.73K | |
| Operating Expenses | 13.20M | 3.95M | 643.04K | 35.96K |
| Operating Income | -13.20M | -3.95M | -643.04K | -35.96K |
| Interest Expense | -4.95K | -16.50K | ||
| Interest & Investment Income | 131.15K | 1.73K | ||
| Currency Exchange Gain (Loss) | -17.52K | -1.07K | 5.37K | 263.00 |
| Other Non Operating Income (Expenses) | -541.34K | -13.68K | -841.00 | |
| EBT Excluding Unusual Items | -13.63M | -3.97M | -655.02K | -35.70K |
| Other Unusual Items | 43.18K | 183.15K | ||
| Pretax Income | -13.63M | -3.92M | -471.87K | -35.70K |
| Net Income | -13.63M | -3.92M | -471.87K | -35.70K |
| Net Income to Common | -13.63M | -3.92M | -471.87K | -35.70K |
| Shares Outstanding (Basic) | 21.54M | 12.64M | 6.73M | 1.74M |
| Shares Outstanding (Diluted) | 21.54M | 12.64M | 6.73M | 1.74M |
| EPS (Basic) | -0.63 | -0.31 | -0.07 | -0.02 |
| EPS (Diluted) | -0.63 | -0.31 | -0.07 | -0.02 |
| Free Cash Flow | -10.61M | -1.69M | -225.44K | -4.29K |
| Free Cash Flow Per Share | -0.49 | -0.13 | -0.03 | -0.00 |
| EBITDA | -13.17M | -3.93M | ||
| D&A For EBITDA | 29.94K | 17.25K | ||
| EBIT | -13.20M | -3.95M | -643.04K | -35.96K |
| Advertising Expenses | 54.39K | 10.46K |
Balance sheet
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 1.97M | 4.81M | 314.62K | |
| Cash & Short-Term Investments | 1.97M | 4.81M | 314.62K | |
| Other Receivables | 2.43K | 2.00M | ||
| Receivables | 2.43K | 2.07M | ||
| Prepaid Expenses | 4.54M | 549.93K | 32.62K | |
| Restricted Cash | 238.21K | 25.16K | ||
| Total Current Assets | 6.76M | 7.46M | 347.24K | |
| Property, Plant & Equipment | 145.96K | 11.24K | ||
| Other Intangible Assets | 164.00K | 176.88K | 186.70K | |
| Long-Term Deferred Charges | 42.18K | |||
| Total Assets | 7.16M | 7.69M | 533.94K | |
| Accounts Payable | 794.75K | 256.30K | 319.02K | 31.19K |
| Accrued Expenses | 34.78K | 76.00K | 13.92K | |
| Short-Term Debt | 381.32K | 3.72K | 7.91K | 4.28K |
| Total Current Liabilities | 1.27M | 336.02K | 340.86K | 35.47K |
| Long-Term Debt | 98.12K | |||
| Total Liabilities | 1.31M | 336.02K | 438.98K | 35.47K |
| Common Stock | 27.40K | 18.91K | 8.53K | 4.16K |
| Additional Paid-In Capital | 22.09M | 11.86M | 684.40K | |
| Retained Earnings | -16.27M | -4.52M | -597.96K | -39.62K |
| Shareholders' Equity | 5.85M | 7.35M | 94.96K | -35.47K |
| Total Liabilities & Equity | 7.16M | 7.69M | 533.94K | |
| Total Debt | 453.80K | 3.72K | 106.03K | 4.28K |
| Net Cash (Debt) | 1.52M | 4.81M | 208.59K | -4.28K |
| Net Cash Per Share | 0.07 | 0.38 | 0.03 | -0.00 |
| Filing Date Shares Outstanding | 28.21M | 18.91M | 18.99M | 1.74M |
| Total Common Shares Outstanding | 27.40M | 18.91M | 8.53M | 1.74M |
| Working Capital | 5.48M | 7.12M | 6.38K | -35.47K |
| Book Value Per Share | 0.21 | 0.39 | 0.01 | -0.02 |
| Tangible Book Value | 5.69M | 7.18M | -91.74K | -35.47K |
| Tangible Book Value Per Share | 0.21 | 0.38 | -0.01 | -0.02 |
| Machinery | 90.51K | 18.67K |
Cash flow statement
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -13.63M | -3.92M | -471.87K | -35.70K |
| Depreciation & Amortization | 39.78K | 17.25K | ||
| Stock-Based Compensation | 6.28M | 2.18M | 7.01K | 211.00 |
| Other Operating Activities | -410.09K | -43.18K | -183.15K | |
| Change in Accounts Payable | 657.88K | 89.42K | 452.02K | 31.19K |
| Change in Income Taxes | 11.96K | -3.04K | ||
| Change in Other Net Operating Assets | -3.55M | 11.20K | -29.45K | |
| Operating Cash Flow | -10.53M | -1.67M | -225.44K | -4.29K |
| Capital Expenditures | -76.23K | -18.67K | ||
| Investing Cash Flow | -107.17K | -89.99K | ||
| Short-Term Debt Issued | 3.64K | 4.28K | ||
| Total Debt Issued | 3.64K | 4.28K | ||
| Short-Term Debt Repaid | -4.19K | |||
| Long-Term Debt Repaid | -94.21K | |||
| Total Debt Repaid | -92.19K | -98.40K | ||
| Net Debt Issued (Repaid) | -92.19K | -98.40K | 3.64K | 4.28K |
| Issuance of Common Stock | 9.35M | 6.42M | 531.00K | 17.00 |
| Other Financing Activities | 2.75M | -42.18K | ||
| Financing Cash Flow | 12.01M | 6.28M | 534.64K | 4.29K |
| Foreign Exchange Rate Adjustments | 3.50K | -3.91K | 5.42K | |
| Net Cash Flow | 1.38M | 4.52M | 314.62K | |
| Free Cash Flow | -10.61M | -1.69M | -225.44K | -4.29K |
| Free Cash Flow Per Share | -0.49 | -0.13 | -0.03 | -0.00 |
| Levered Free Cash Flow | -5.40M | -3.75M | ||
| Unlevered Free Cash Flow | -5.40M | -3.74M | ||
| Cash Interest Paid | 17.55K | 17.55K | ||
| Change in Working Capital | -2.88M | 97.59K | 422.57K | 31.19K |
Ratios
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Debt / Equity Ratio | 0.08 | 0.00 | 1.12 | -0.12 |
| Net Debt / Equity Ratio | -0.26 | -0.65 | -2.20 | -0.12 |
| Net Debt / EBITDA Ratio | 0.12 | 1.22 | ||
| Net Debt / FCF Ratio | 0.14 | 2.85 | 0.93 | -1.00 |
| Quick Ratio | 1.55 | 20.27 | 0.92 | |
| Current Ratio | 5.31 | 22.20 | 1.02 | |
| Return on Equity (ROE) | -332.94% | -105.36% | -1,586.27% | |
| Return on Assets (ROA) | -170.73% | -60.03% | ||
| Return on Capital Employed (ROCE) | -224.30% | -53.70% | -333.00% | 101.40% |
| Buyback Yield / Dilution | -112.91% | -87.74% | -286.25% |